[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN112703013A - Cd3抗原结合片段及其应用 - Google Patents

Cd3抗原结合片段及其应用 Download PDF

Info

Publication number
CN112703013A
CN112703013A CN201980050849.0A CN201980050849A CN112703013A CN 112703013 A CN112703013 A CN 112703013A CN 201980050849 A CN201980050849 A CN 201980050849A CN 112703013 A CN112703013 A CN 112703013A
Authority
CN
China
Prior art keywords
amino acid
seq
nos
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980050849.0A
Other languages
English (en)
Other versions
CN112703013B (zh
Inventor
张敬
方丽娟
严永祥
曾亮
周鹏飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan Yzy Biopharma Co ltd
Original Assignee
Wuhan Yzy Biopharma Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan Yzy Biopharma Co ltd filed Critical Wuhan Yzy Biopharma Co ltd
Priority to CN202211447908.8A priority Critical patent/CN116178547A/zh
Publication of CN112703013A publication Critical patent/CN112703013A/zh
Application granted granted Critical
Publication of CN112703013B publication Critical patent/CN112703013B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本申请提供了人源化和多功能CD3抗体，其中包括的CD3的重链可变区包含SEQ ID NOs:1‑3中任一条的氨基酸序列或其变体序列，轻链可变区包含SEQ ID NOs:26‑28中任一条的氨基酸序列或其变体序列。本申请还提供了一种多功能抗体，该抗体包括(a)轻链‑重链对，该轻链‑重链对针对肿瘤细胞或微生物具有特异性；和(b)融合肽，该融合肽包括单链可变片段和具有CH2结构域和/或CH3结构域的Fc片段，其中该融合肽针对免疫细胞具有特异性。本申请提供的抗体具有改善的生物学活性、热稳定性和/或耐酸性。

Description

PCT国内申请，说明书已公开。

Claims (31)

  1. PCT国内申请，权利要求书已公开。
CN201980050849.0A 2019-02-22 2019-02-22 Cd3抗原结合片段及其应用 Active CN112703013B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211447908.8A CN116178547A (zh) 2019-02-22 2019-02-22 Cd3抗原结合片段及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/075901 WO2020168555A1 (zh) 2019-02-22 2019-02-22 Cd3抗原结合片段及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211447908.8A Division CN116178547A (zh) 2019-02-22 2019-02-22 Cd3抗原结合片段及其应用

Publications (2)

Publication Number Publication Date
CN112703013A true CN112703013A (zh) 2021-04-23
CN112703013B CN112703013B (zh) 2022-09-30

Family

ID=72144856

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211447908.8A Pending CN116178547A (zh) 2019-02-22 2019-02-22 Cd3抗原结合片段及其应用
CN201980050849.0A Active CN112703013B (zh) 2019-02-22 2019-02-22 Cd3抗原结合片段及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202211447908.8A Pending CN116178547A (zh) 2019-02-22 2019-02-22 Cd3抗原结合片段及其应用

Country Status (7)

Country Link
US (1) US11639388B2 (zh)
EP (1) EP3928790A4 (zh)
JP (2) JP2022530301A (zh)
KR (1) KR20210142638A (zh)
CN (2) CN116178547A (zh)
CA (1) CA3131036A1 (zh)
WO (1) WO2020168555A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222027A1 (zh) * 2022-05-18 2023-11-23 三生国健药业（上海）股份有限公司 一种抗trop-2/cd3双特异性抗体

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180077271A (ko) * 2015-11-03 2018-07-06 암브룩스, 인코포레이티드 항-ｃｄ3-폴레이트 컨쥬게이트 및 이의 용도
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN112010982B (zh) * 2020-08-31 2023-06-27 重庆金迈博生物科技有限公司 一种抗gpc3/cd3双特异性抗体及其应用
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN115894701A (zh) * 2021-09-30 2023-04-04 上海君实生物医药科技股份有限公司 结合cd3的抗体及其用途
CN114316062B (zh) * 2022-03-02 2022-06-07 珠海臻谱基因科技有限公司北京分公司 靶向HIV gp120蛋白和人CD3分子的多特异性抗体及其应用
WO2024108032A2 (en) * 2022-11-18 2024-05-23 Jn Biosciences Llc Anti-cd3 antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019620A1 (en) * 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
WO2013158856A2 (en) * 2012-04-20 2013-10-24 Emergent Product Development Seattle, Llc Cd3 binding polypeptides
CN104592392A (zh) * 2015-01-21 2015-05-06 武汉友芝友生物制药有限公司 一种双特异性抗体EpCAM×CD3的构建及应用
WO2017023761A1 (en) * 2015-07-31 2017-02-09 Regeneron Pharmaceuticals, Inc. Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
KR100516133B1 (ko) 1997-04-14 2005-09-21 마이크로메트 에이지 항-인간항원 수용체의 신규한 제조방법 및 용도
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
DE69934967T2 (de) 1998-12-08 2007-12-06 Biovation Ltd. Verfahren zur verminderung der immunogenität von proteinen
US8846042B2 (en) * 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
PL2714733T3 (pl) * 2011-05-21 2019-08-30 Macrogenics, Inc. Cząsteczki wiążące CD3 zdolne do wiązania z ludzkim i nieludzkim CD3
EP2922874A4 (en) * 2012-11-21 2016-10-19 Wuhan Yzy Biopharma Co Ltd BISPECIFIC ANTIBODIES
US10131710B2 (en) * 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
CN106471009B (zh) * 2014-03-28 2020-01-03 Xencor公司 结合至cd38和cd3的双特异性抗体
BR112017001579A2 (pt) * 2014-07-25 2017-11-21 Cytomx Therapeutics Inc anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
AU2015312117A1 (en) * 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
KR20240148942A (ko) * 2015-01-08 2024-10-11 젠맵 에이/에스 Cd3 및 cd20에 대항한 이중특이적 항체
JP2019506398A (ja) * 2016-01-21 2019-03-07 ファイザー・インク 上皮増殖因子受容体変異体ｉｉｉおよびｃｄ３の単一および二重特異性抗体およびそれらの使用
EP3430058A4 (en) * 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
EP3475304B1 (en) * 2016-06-28 2022-03-23 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
CN110770255A (zh) * 2017-04-11 2020-02-07 印希彼有限公司 具有受限cd3结合的多特异性多肽构建体及其使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019620A1 (en) * 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
WO2013158856A2 (en) * 2012-04-20 2013-10-24 Emergent Product Development Seattle, Llc Cd3 binding polypeptides
CN104592392A (zh) * 2015-01-21 2015-05-06 武汉友芝友生物制药有限公司 一种双特异性抗体EpCAM×CD3的构建及应用
WO2017023761A1 (en) * 2015-07-31 2017-02-09 Regeneron Pharmaceuticals, Inc. Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222027A1 (zh) * 2022-05-18 2023-11-23 三生国健药业（上海）股份有限公司 一种抗trop-2/cd3双特异性抗体

Also Published As

Publication number Publication date
JP2022530301A (ja) 2022-06-29
WO2020168555A1 (zh) 2020-08-27
US11639388B2 (en) 2023-05-02
EP3928790A4 (en) 2023-01-11
CN112703013B (zh) 2022-09-30
KR20210142638A (ko) 2021-11-25
EP3928790A1 (en) 2021-12-29
US20220041721A1 (en) 2022-02-10
JP2023106392A (ja) 2023-08-01
CA3131036A1 (en) 2020-08-27
CN116178547A (zh) 2023-05-30

Similar Documents

Publication Publication Date Title
CN112703013B (zh) Cd3抗原结合片段及其应用
CN110914296B (zh) 改造的Fc片段，包含其的抗体及其应用
CN104271602B (zh) 双特异性抗体
KR102365972B1 (ko) 항-pd-1 항체 및 이의 용도
WO2020107715A1 (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
CN117098561A (zh) Ccr8抗体及其应用
KR20150030675A (ko) 항ｂｍｐ９ 항체를 유효 성분으로 하는, 신장성 빈혈, 암성 빈혈 등의 빈혈에 대한 치료제
TW202017945A (zh) 抗ｃｄ７３抗體、其抗原結合片段及應用
CN111848809A (zh) 靶向Claudin18.2的CAR分子、其修饰的免疫细胞及用途
WO2022068810A1 (zh) 抗Claudin18.2和CD3的双特异性抗体以及其用途
JP2021527683A (ja) ヒトインターロイキン１８受容体アルファおよびベータに対するヒト抗体
WO2021097800A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
JP2021530511A (ja) 抗ｐｄ−１抗体、投薬量、およびその使用
CN117062834A (zh) Gpc3人源化抗体及其应用
KR20230005001A (ko) 메소텔린 특이적 항체 및 이의 용도
CN114437227A (zh) 双特异抗体及其应用
CN115947855B (zh) 抗cd24抗体的制备及其用途
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途
CN116903757B (zh) Cd70纳米抗体和双靶向嵌合抗原受体
CN115521379B (zh) Pd-1抗体及其用途
CN114773485B (zh) 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
WO2024109657A1 (zh) 抗ccr8抗体及其用途
TW202413437A (zh) 特異性結合ｇｕｃｙ２ｃ和ｃｄ３的抗原結合分子及其醫藥用途
TW202430559A (zh) 靶向cd70的抗體或結合cd70的抗原結合片段及其製備方法和應用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: C2-1, Optics Valley Biological City, 666 Gaoxin Avenue, Donghu Technological Development Zone, Wuhan City, Hubei Province, 430075

Applicant after: Wuhan youzhiyou biopharmaceutical Co.,Ltd.

Address before: C2-1, Optics Valley Biological City, 666 Gaoxin Avenue, Donghu Technological Development Zone, Wuhan City, Hubei Province, 430075

Applicant before: WUHAN YZY BIOPHARMA Co.,Ltd.

GR01 Patent grant
GR01 Patent grant